Pacira BioSciences (PCRX) Cash & Equivalents (2010 - 2026)

Pacira BioSciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $144.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 49.12% year-over-year to $144.3 million in Q1 2026; TTM through Mar 2026 was $144.3 million, a 49.12% decrease from a year earlier, with the FY2025 full-year figure at $158.5 million, down 42.72% from the prior year.
• Cash & Equivalents declined to $144.3 million in Q1 2026 per PCRX's latest filing, from $158.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $300.5 million in Q2 2025 and bottomed at $35.5 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $153.3 million (2023), against an average of $172.1 million.
• Across the five-year window, Cash & Equivalents plunged 84.32% in 2023 and soared 417.8% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $104.1 million in 2022, then soared by 47.21% to $153.3 million in 2023, then jumped by 80.55% to $276.8 million in 2024, then sank by 42.72% to $158.5 million in 2025, then retreated by 8.98% to $144.3 million in 2026.
• Per Business Quant, the three latest PCRX Cash & Equivalents figures stand at $144.3 million (Q1 2026), $158.5 million (Q4 2025), and $147.6 million (Q3 2025).